Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1056/nejmoa0801479 | Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma |
| https://doi.org/10.1056/nejmoa1112704 | Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma |
| https://doi.org/10.1038/leu.2017.138 | Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study |
| https://doi.org/10.1111/j.1600-0609.2010.01533.x | Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study |
| https://doi.org/10.1111/j.1600-0609.2011.01599.x | Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma |
| https://doi.org/10.1038/s41409-021-01464-x | Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS) |
| https://doi.org/10.1182/blood.v118.21.476.476 | Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial |
| https://doi.org/10.3389/fimmu.2023.1106464 | Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis |
| https://doi.org/10.1182/blood.v128.22.4414.4414 | Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study |
| https://doi.org/10.1182/blood.v112.11.650.650 | Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma |
| https://doi.org/10.1182/blood.v112.11.54.54 | Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter Trial |
| https://doi.org/10.1182/blood.v124.21.80.80 | Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma |
| https://doi.org/10.1182/blood.v112.11.2778.2778 | Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone |
| https://doi.org/10.1038/s41409-019-0458-8 | Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres |
| https://doi.org/10.1182/blood.v112.11.157.157 | Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM) |
| https://doi.org/10.1182/blood.v114.22.3859.3859 | Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use. |
| https://doi.org/10.1182/blood.v112.11.1727.1727 | Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study. |
| https://doi.org/10.1182/blood.v124.21.4770.4770 | Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma |
| https://doi.org/10.1182/blood.v110.11.76.76 | MMY-3002: A Phase 3 Study Comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in Newly Diagnosed Multiple Myeloma. |
| https://doi.org/10.1182/blood.v108.11.5241.5241 | Palifermin Treatment in Patients Receiving High Dose Melphalan or BEAM Prior to Autologous Peripheral Blood Stem-Cell Transplantation. |
| https://doi.org/10.1182/blood.v112.11.1741.1741 | Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial. |
| https://doi.org/10.1179/acb.2010.055 | THE BELGIAN 2010 CONSENSUS RECOMMENDATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| https://doi.org/10.1182/blood.v104.11.5046.5046 | Fludarabine Phosphate-Based Nonmyeloablative Stem Cell Transplantation in the Elderly Patients: A BHS Study. |